(Total Views: 721)
Posted On: 03/06/2021 12:03:05 AM
Post# of 145247
Without adequate power, that 24% reduction is not a reliable number. Based on statistics, with such a low power, leronlimab could have reduced mortality by 23% partially due to chance. Sorry but that's just how the FDA will view the numbers. Janet Woodcock has continually reinforced that they are interested in adequately powered trials.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)